Eastern Cooperative Oncology Group
Trial Pipeline
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
NCT06756607
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
NCT05289687
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01415752
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
NCT00978458
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
NCT01079780
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00274924
Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
NCT00090974
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
NCT00060398
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
NCT00053209
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
NCT00027859
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
NCT00040807
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00041314
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
NCT00033657
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00028990
Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
NCT00025350
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00006385
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00006008
Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
NCT00005045
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
NCT00004223
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
NCT00003871
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
NCT00003308
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
NCT00003518
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
NCT00003129
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
NCT00003138
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00003150
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
NCT00002868
Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix
NCT00003017
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
NCT00002888
Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer
NCT00002667
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 18 |
| Phase 3 | 8 |
Therapeutic Areas
What the Pipeline for Eastern Cooperative Oncology Group Shows
According to the ClinicalTrials.gov registry, Eastern Cooperative Oncology Group is linked to 30 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 10% of the sponsor's indexed portfolio — and 25 are already marked complete, representing roughly 83% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Eastern Cooperative Oncology Group reports 8 late-stage studies (Phase 3 and Phase 4 combined) and 18 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Eastern Cooperative Oncology Group is Bladder Cancer with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.